Estrinorm

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Estrinorm

Estrinorm is a specialized, single-component prescription medicine used as an estrogen within the category of hormone replacement therapy (HRT) agents. Its primary role is to supplement the body with a specific type of sex hormone that has declined.


Quick Facts

Property Description
Active ingredient Estriol (INN)
Form Oral tablet
Pharmacological class Estrogens / Sex Hormones
Common purpose Hormone restoration
Origin Naturally occurring steroid hormone (API is synthetic)

What Type of Medicine is Estrinorm?

Estrinorm is formally classified under the high-level pharmacological group of Estrogens / Sex Hormones, a category utilized for therapeutic hormone restoration. It is defined as an HRT agent because it provides the body with the active substance Estriol (E3), one of the main estrogens naturally produced by the human body. This classification is clinically recognized for addressing deficiencies and differentiates it from non-hormonal treatments.


Composition and Form: Estriol’s Unique Characteristics

The medication is a monosemiotic preparation containing only the active ingredient Estriol, which is a naturally occurring human steroid hormone. Although Estriol itself is a natural compound, the active pharmaceutical ingredient (API) used in the product is manufactured synthetically for pharmaceutical stability and purity. Estrinorm is supplied as a solid oral tablet, intended to be taken via the oral route of administration. Unlike formulations containing estradiol, Estriol is known in pharmacological studies for its distinctive, relatively weak estrogenic action.


General Purpose and Differentiation

The general purpose of Estrinorm is to provide hormone restoration to help alleviate physical changes linked to estrogen deficiency conditions in postmenopausal women. Estriol is chemically differentiated from other estrogens by its specific selective action, a key feature that has been repeatedly highlighted in endocrinology literature. This medication has a specific, highly targeted action profile. This focused trophic effect is utilized as the drug’s differentiating factor, providing targeted support for the health and structural integrity of sensitive tissues.

What side effects are possible with Estrinorm?

Possible Side Effects and Safety Information

The official safety information for Estrinorm (Estriol, oral tablet) is structured by regulatory agencies to address both common, expected adverse reactions and the specific serious risks associated with all systemic estrogen-only Hormone Replacement Therapy (HRT) agents.


Official Adverse Reaction Scope

Adverse reactions are classified by frequency and body system according to regulatory documents:

Classification Examples of Documented Effects
Common Breast discomfort or tenderness, headache, and nausea.
Uncommon Fluid retention leading to edema, and changes in body weight.

Serious risks associated with the systemic use of estrogens are consistently cited in official warnings and classified under the Vascular and Neoplastic system-organ classes. These serious reactions include Venous Thromboembolism (VTE), Stroke, and an increased risk of certain cancers, specifically Endometrial Cancer (in women with a uterus), Breast Cancer, and Ovarian Cancer.


Safety Constraints and Patterns

The regulatory labeling includes specific constraints and observations related to the use and duration of treatment:

  • Duration-Related Pattern: The risk of VTE is cited as being more likely during the first year of use of systemic HRT.
  • Age-Related Constraint: The risk of probable dementia is associated with initiation of HRT in women aged 65 or older.
  • Population Constraints: Safety constraints apply to patients with severe hepatic impairment and to those with conditions sensitive to fluid retention, such as cardiac or renal dysfunction. Monitoring of blood pressure is required during therapy.

This regulatory structure emphasizes that the risk of serious vascular events and estrogen-related cancers are documented characteristics of the drug class.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information for Estrinorm (Estriol), classified as an estrogen, mandates that immediate medical attention must be sought upon any suspected overdose or accidental high exposure. Management of an overdose focuses strictly on supportive care as no specific antidote is known.


Documented Clinical Manifestations

Element Regulatory Description (Estrogen Class)
Documented Presentations Nausea, vomiting, breast tenderness, abdominal pain, headache, drowsiness, and fluid retention.
Severe Outcome Note Withdrawal bleeding (excessive vaginal bleeding) is a documented manifestation; serious symptoms are noted as generally very unlikely.

Official Emergency Response

The most important immediate action is to seek medical help right away and contact a poison control center or emergency room at once. The regulatory protocol requires discontinuation of the product, followed by institution of appropriate symptomatic and supportive care.

Monitoring protocols include checking the person's vital signs and may involve using activated charcoal in extreme cases. Urgent help is required based on the official determination that any suspected overdose necessitates immediate professional medical assessment.

Therapeutic Uses of Estrinorm

What Estrinorm Treats: Main Uses and Benefits

Estrinorm (Estriol) is an HRT agent used to provide highly targeted support by addressing symptoms related to physical discomfort resulting from estrogen deficiency in postmenopausal women, focusing solely on the therapeutic needs of the urogenital tract. The primary therapeutic domain is the management of symptoms related to vaginal atrophy.


The medication is relevant for managing conditions characterized by periods of heightened symptoms and is commonly used for Vulvovaginal Atrophy (VVA) and associated manifestations of Genitourinary Syndrome of Menopause (GSM). This is relevant for managing symptom clusters that may become intense or disruptive, such as persistent vaginal dryness, burning, irritation, and dyspareunia (pain during intercourse), as well as associated lower urinary tract symptoms like urinary urgency and frequency. This contributes to easing the overall symptom load and supports the patient during difficult episodes by easing distress. The medication is commonly applied when symptoms interfere with daily functioning, assisting with maintaining functional stability.


Quick Fact: Support for Atrophy Symptoms Estrinorm is commonly used to help with chronic, progressive atrophic symptoms that affect both intimate comfort and lower urinary tract function.

Eligibility and Restrictions for Use

Estrinorm (Estriol) is officially designated for use in postmenopausal women to address estrogen deficiency symptoms. Its eligibility is strictly governed by authoritative regulatory classifications that define both the intended population and absolute exclusions.

Populations for whom use is contraindicated (Must Not Use): Use is absolutely prohibited for women with a known or suspected history of breast cancer or other estrogen-dependent malignant tumours. The medicine is also contraindicated in the presence of undiagnosed genital bleeding, untreated endometrial hyperplasia, or active diseases such as venous thromboembolism (VTE), arterial thromboembolic disease (e.g., stroke), or acute liver disease where liver function has not normalized.

Age and Physiological Status Rules:

  • Pediatric Use: The medicine is not applicable to children or adolescents.
  • Pregnancy and Lactation: Use is contraindicated during pregnancy and not recommended during breastfeeding.

Conditional Use (Requires Close Supervision): Eligibility is conditional for patients with specific pre-existing conditions that require close monitoring, including leiomyoma (fibroids), endometriosis, hypertension, diabetes mellitus, and migraine or severe headaches. The regulatory context dictates that therapy must be immediately withdrawn if a new contraindication is discovered.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Estrinorm (estradiol) is metabolized by the Cytochrome P450 3A4 (CYP3A4) enzyme system in the liver, which is the primary mechanistic basis for its clinically significant drug interactions. This metabolism means the medication is sensitive to other products that either speed up (inducers) or slow down (inhibitors) the activity of this enzyme.

Interactions that may reduce Estrinorm's effectiveness

CYP3A4 Inducers accelerate the metabolism of estradiol, potentially decreasing its concentration in the bloodstream. This may result in reduced therapeutic effect.

  • Medicinal Products: Specific anticonvulsants such as carbamazepine and phenobarbital, and the antibiotic rifampin, are documented CYP3A4 inducers.
  • Herbal Products: The herbal supplement St. John’s Wort is also classified as a CYP3A4 inducer that may lower estrogen levels.

Interactions that may increase side effects

CYP3A4 Inhibitors may increase the plasma concentration of estradiol by slowing its breakdown. Examples include certain antifungal agents (like ketoconazole and itraconazole) and macrolide antibiotics (like erythromycin and clarithromycin).

Other Documented Interactions

  • Lamotrigine: Estradiol may decrease the plasma concentration of lamotrigine, an anticonvulsant, which can potentially increase the risk of seizures.
  • Thyroid Hormones: Estradiol can increase levels of thyroid-binding globulin, potentially leading to a reduced amount of free thyroid hormone. This may decrease the effectiveness of thyroid replacement therapies like levothyroxine, and patients may require a dosage adjustment for the thyroid medication.
  • Benzodiazepines: The effects of benzodiazepines (such as diazepam, lorazepam, temazepam, and triazolam) may be unpredictably increased or decreased when taken with estradiol.

Mechanism of Action

Estrinorm, containing estriol, functions as an estrogen receptor (ER) agonist. The molecule is a hydroxylated metabolite of estradiol that selectively targets and binds to intracellular estrogen receptors, primarily ERalpha and ERbeta, found in estrogen-responsive tissues, including the lower genitourinary tract.

Upon binding, the estriol-receptor complex undergoes dimerization, translocates to the cell nucleus, and interacts with specific DNA sequences known as Estrogen Response Elements (EREs) in the promoter regions of target genes. This binding modulates gene transcription, leading to the formation of messenger RNA (mRNA) and subsequent synthesis of specific cellular proteins. This genomic signaling cascade regulates cellular proliferation and differentiation, particularly in epithelial and stromal cells of the targeted tissues. Additionally, estriol can exert non-genomic effects by binding to membrane-associated ERs, activating rapid intracellular signaling pathways like protein kinase cascades. The overall systemic physiological consequence involves the modulation of protein expression patterns characteristic of estrogen action.

Dosage and Administration Information

Estrinorm (Estriol) is an oral medication that must be swallowed whole with water as directed by prescribing information. The total daily amount is intended to be taken once per day, preferably at a consistent time each day to maintain a stable administration schedule. The prescribed use of this preparation establishes a structure with initial, higher dosing, followed by a lower maintenance phase.


Official Dosing Regimens

Treatment Phase Daily Dose Range Context
Initial Use 4 mg to 8 mg Typically for the first few weeks of therapy to establish control.
Maintenance Use 1 mg to 2 mg The dose is gradually reduced after the initial phase, based on response.
Peri-operative 4 mg (Pre) / 1 mg (Post) Specific short-term regimens for 2 weeks before and 2 weeks after vaginal surgery.

Administration and Missed Dose Guidance

The medication is supplied as an oral tablet. The score line present on the tablet is intended to assist in swallowing and is not for dividing the tablet into exact fractional doses. The daily dose must be taken in a single, undivided intake.

If a dose is forgotten, it should be taken immediately upon remembering, unless the delay exceeds 12 hours. If the lapse is more than 12 hours, the missed dose must be skipped entirely, and the normal dosing schedule must be resumed the following day. A double dose should not be taken to compensate for a missed administration.

Recent Clinical Evidence

Research evidence / Overview of studies for Estrinorm

Evidence for Use in Vulvovaginal Atrophy (VVA) and GSM Symptoms

Research exploring the active ingredient in Estrinorm, Estriol, for symptoms related to Vulvovaginal Atrophy (VVA) and Genitourinary Syndrome of Menopause (GSM) has primarily relied on Randomized Controlled Trials (RCTs). These studies compare patient groups receiving the medicine to those receiving a placebo, and their findings are often combined in systematic reviews to understand broad patterns.

Studies were designed to observe how symptoms evolved in the observed populations. Research examined patient-reported outcomes describing perceived discomfort, such as vaginal dryness and pain during intercourse. Findings describe patterns observed in the studies where objective clinical measures were monitored, including measurements of the Vaginal Maturation Index (VMI) (which assesses epithelial cell composition) and changes in vaginal pH levels.


What Outcomes Were Measured in Clinical Trials?

Studies monitored specific objective clinical endpoints and functional outcomes. Estrinorm was studied for how its use may affect physiological markers. Measurements of systemic hormone levels (including Estriol, Estrone, and Estradiol) were also taken in some trials to assess the amount of Estriol that appears to be absorbed into the bloodstream, which varied depending on the formulation and dose used.


Research Landscape: Oral vs. Local Formulations

The evidence level is categorized as High for the general research base related to the active ingredient (Estriol) for VVA/GSM symptoms. However, a key limitation is that the majority of robust RCTs were conducted using local (vaginal) formulations of Estriol. While the oral tablet form was studied for its systemic and local effects, comparative evidence for the oral form is limited when compared to the most common vaginal delivery methods. The research findings reflect the specific conditions and populations under which they were studied.


Key Limitations and Areas of Uncertainty

The follow-up durations were limited in most primary clinical trials, with common observation periods around 12 weeks. Longer-term effects are not fully established because data collection covering outcomes beyond one year is limited. Furthermore, the trials were generally not designed or statistically powered to investigate rare, long-term systemic safety endpoints, such as major vascular events. Comparative evidence is limited for the oral tablet form against many other standard treatments.

Key Studies & References Study Evaluating the Efficacy and Safety of Three Formulations of Ultra-low Dose Estriol Vaginal Gel... (NCT02967510)

Frequently Asked Questions (FAQ)

Common questions about Estrinorm (FAQ)

Q: Does taking Estrinorm cause weight gain?

Official documentation mentions 'changes in body weight' as an uncommon adverse reaction associated with the use of this medicine. Other safety data may specifically categorize weight gain as one of the reported side effects.


Q: Can Estrinorm affect my mood or cause anxiety?

While mood changes or anxiety may not be listed among the most common adverse reactions, regulatory data for the estrogen class of drugs has sometimes cited related neurological symptoms. These may include irritability, nervousness, or, in some cases, dizziness.


Q: Is it common to have mild headaches when first starting Estrinorm?

Headache is listed as a common adverse reaction in official safety documents. However, the regulatory documentation does not typically specify if headaches are more likely to occur immediately after beginning treatment compared to later in the course of therapy.


Q: Is there evidence for Estrinorm helping with symptoms besides its main use?

Research and official indications primarily focus on the approved uses for vulvovaginal atrophy and genitourinary symptoms. Historically, some studies have also examined the drug's effect on general menopausal symptoms, such as hot flashes and insomnia.


Q: Can using Estrinorm make me feel tired or fatigued?

Official safety information lists fatigue or unusual tiredness as a potential reported side effect. This type of effect may be noted in safety surveillance data, even if it is not categorized as one of the most frequently occurring adverse events.


Q: What happens if I stop taking Estrinorm suddenly?

Regulatory information indicates that withdrawal bleeding can occur when the medicine is discontinued. Because treatment is generally meant to be gradually reduced to a maintenance dose, regulatory documents do not specifically detail the full consequences of sudden cessation, aside from the potential return of original symptoms.


Q: If I am having surgery, do I need to stop taking Estrinorm beforehand?

Regulatory guidance for systemic estrogen therapy often states that the medicine may need to be temporarily stopped. This is typically done before and immediately after major surgery or during periods of prolonged immobilization to help reduce the risk of venous thromboembolism (VTE), which is a serious blood clot risk associated with the drug class.


Q: Can Estrinorm affect the results of blood tests?

Yes, regulatory documentation states that estrogens, including estriol, can affect the results of certain laboratory tests. For example, they may cause an increase in levels of thyroid-binding globulin, which can influence the interpretation of thyroid function test results.


Q: Is it possible for Estrinorm to interact with alcohol?

While alcohol may not always be listed in the formal Drug Interactions section, official patient warnings for estrogen products sometimes advise consulting a physician about alcohol intake. Official warnings about cardiovascular risk factors often include alcohol use when discussing systemic hormone replacement therapy.


Q: How long does Estrinorm stay in my system after I stop taking it?

The active ingredient, estriol, has a reported elimination half-life of approximately 5 to 10 hours for the oral formulation. This pharmacokinetic data suggests that the drug is cleared from the bloodstream relatively quickly after the last dose.


Q: Can Estrinorm affect fertility or conception?

Official regulatory documents state that the medicine is contraindicated (must not be used) during pregnancy and is not recommended during breastfeeding. Furthermore, some patient warnings for estrogen-containing products include an instruction not to use the medicine when a patient is actively trying to conceive.


Q: Is there a specific period of time recommended for monitoring side effects after starting the drug?

Official prescribing information describes the requirement for regular medical check-ups while on therapy. Additionally, regulatory documents state that the risk for serious adverse events, such as venous thromboembolism (VTE), is cited as being more likely during the first year of use.


Q: What are the general expectations for benefits when starting Estrinorm?

According to the official product information, the primary clinical expectation is the relief of symptoms related to estrogen deficiency. The drug is formally indicated for use in addressing specific symptoms, particularly those affecting the lower genitourinary tract.


Q: Does the time of day matter when taking Estrinorm?

Official instructions specify that the medicine should be taken once per day at a consistent time each day. While regulatory documents do not usually mandate a specific time (morning versus evening), consistency is advised to help maintain stable drug administration levels.


Q: If I experience a rare side effect, is there an official way to report it?

Yes, regulatory agencies worldwide have created established formal systems for safety surveillance. Patients and healthcare providers can voluntarily report any suspected adverse reactions, including rare or unexpected ones, through mechanisms like the FDA's MedWatch or the UK's Yellow Card Scheme.


Q: What is considered an 'overdose' of Estrinorm?

Overdosage is typically defined as the intake of an excessively high amount of the medicine. Regulatory documents for estrogen overdose describe potential symptoms which may include nausea, vomiting, breast tenderness, abdominal pain, and sometimes feelings of drowsiness or fatigue.


Q: Why is Estrinorm sometimes prescribed instead of an older medicine?

The drug's active ingredient, estriol, is noted in pharmacological studies for its relatively weak and targeted estrogenic action. This selective action profile, compared to other, more potent estrogens, is a key characteristic that may be considered during the prescribing process.


Q: Is it true that Estrinorm is only for a specific gender?

Yes, the official regulatory indications and target populations for Estrinorm are strictly defined for use in postmenopausal women to address symptoms of estrogen deficiency in that population.


Q: How does the drug name 'Estrinorm' relate to its function or components?

The brand name 'Estrinorm' likely incorporates the root 'Estrin-', which refers to the estrogen class of hormones (Estriol). The suffix '-norm' may suggest a function related to normalizing or restoring depleted hormone levels.


Q: Are there special warnings for people with certain lifestyle habits (e.g., smoking)?

Yes, regulatory documents for systemic estrogen therapies advise that the risks for serious side effects, particularly venous thromboembolism (VTE), may be further increased by existing cardiovascular risk factors. These risk factors generally include habits such as smoking.


How should Estrinorm be stored and disposed of?

Regulatory documents for estriol-containing products define specific conditions for storage, handling, and disposal.

Storage Requirements

Condition Classification (Official Labeling)
Temperature Store below 25 C or 30 C. Do not freeze.
Protection Keep in the original container or carton to protect from light.
Child Safety mathbfKeep out of the reach and sight of children.
Handling Clean reusable applicators after each use with warm, soapy water; do not use boiling water.

Disposal Instructions

Official disposal rules forbid placing the unused medicinal product in household waste or flushing it down the toilet, as it may pose a risk to the aquatic environment. Unused or expired medication must be returned to a pharmacy or disposed of according to local waste collection requirements. Empty containers, such as the cream tube, may be disposed of in household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Estrinorm found in:

A-Z Index: